Apolipoprotein E (APOE) Peptide
APOE
Reactivity: Human
Host: Synthetic
BP, IHC, WB
-
- Target See all APOE products
- APOE (Apolipoprotein E (APOE))
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-APOE antibody (Catalog #: ARP54283_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
Apolipoprotein E (APOE) peptide
APOE Reactivity: Human Host: Synthetic BP, Imm
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- APOE (Apolipoprotein E (APOE))
- Synonyms
- ad2 Peptide, apoprotein Peptide, im:7036787 Peptide, wu:fb69a05 Peptide, zgc:110064 Peptide, apoe Peptide, AI255918 Peptide, AD2 Peptide, LDLCQ5 Peptide, LPG Peptide, APOEA Peptide, Apo-E Peptide, apolipoprotein E Peptide, apolipoprotein Ea Peptide, apoe Peptide, apoea Peptide, Apoe Peptide, APOE Peptide
- Background
-
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alias Symbols: AD2, MGC1571, apoprotein, LPG, LDLCQ5
Protein Interaction Partner: CNTF,CNTF,HCVgp1,A2M,ALB,APOE,APP,CNTF,CTSB,LDLR,LRP1,LRP2,LRP8,MAP2,MAPT,NEFM,PLTP,PRNP,SCARB1,VLDLR,A2M,LRP2,LRP8,MAPT,NEFM,PLTP
Protein Size: 317 - Molecular Weight
- 34 kDa
- Gene ID
- 348
- NCBI Accession
- NM_000041, NP_000032
- UniProt
- P02649
-
You are here:
